We are live on ! Find out more
MYGN icon

Myriad Genetics
MYGN

270 hedge funds and large institutions have $2.38B invested in Myriad Genetics in 2013 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 109 increasing their positions, 90 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 90

1% more funds holding

Funds holding: 267 → 270 (+3)

6% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 48

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less capital invested

Capital invested by funds: $2.62B → $2.38B (-$245M)

74% less call options, than puts

Call options by funds: $43.4M | Put options by funds: $168M

Holders
270
Holders Change
+3
Holders Change %
+1.12%
% of All Funds
7.84%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
51
Increased
109
Reduced
90
Closed
48
Calls
$43.4M
Puts
$168M
Net Calls
-$125M
Net Calls Change
-$87.4M

Top Buyers

1
LCG
Luxor Capital Group
New York
+$73.2M
2
FTCM
Fir Tree Capital Management
New York
+$55.6M
3
Capital Research Global Investors
Capital Research Global Investors
California
+$47.8M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$38.8M
5
SCM
Snow Capital Management
Pennsylvania
+$38.6M

Top Sellers

1
MNA
Manning & Napier Advisors
New York
-$173M
2
Renaissance Technologies
Renaissance Technologies
New York
-$54.9M
3
SFM
Systematic Financial Management
New Jersey
-$54.5M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$26.2M
5
Goldman Sachs
Goldman Sachs
New York
-$26.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
1
Royce & Associates
New York
$227M -$4.14M -163,500 -1%
BTS
2
BB&T Securities
Virginia
$186M +$1.6M +63,120 +8%
Capital Research Global Investors
3
Capital Research Global Investors
California
$160M +$47.8M +1,888,185 +33%
Vanguard Group
4
Vanguard Group
Pennsylvania
$102M +$1.15M +45,402 +0.9%
Baillie Gifford & Co
5
Baillie Gifford & Co
United Kingdom
$95.4M +$22.4M +885,300 +24%
LCG
6
Luxor Capital Group
New York
$69.2M +$73.2M +2,894,448 +716%
MCM
7
Munder Capital Management
Michigan
$62.9M -$831K -32,850 -1%
SCM
8
Sterling Capital Management
North Carolina
$55M +$5.91M +233,618 +10%
FTCM
9
Fir Tree Capital Management
New York
$46.1M +$55.6M +2,197,371 New
BIT
10
BlackRock Institutional Trust
California
$45.5M +$4.37M +172,634 +9%
State Street
11
State Street
Massachusetts
$41.6M -$4.44M -175,664 -8%
Schroder Investment Management Group
12
Schroder Investment Management Group
United Kingdom
$39.9M +$38.8M +1,535,300 +416%
BA
13
BlackRock Advisors
Delaware
$39.6M +$1.34M +52,941 +3%
First Trust Advisors
14
First Trust Advisors
Illinois
$37.6M +$7.57M +299,334 +20%
TAM
15
Tiverton Asset Management
Delaware
$37.4M – – –
Fidelity Investments
16
Fidelity Investments
Massachusetts
$33.3M +$255K +10,063 +0.6%
SCM
17
Snow Capital Management
Pennsylvania
$32.3M +$38.6M +1,524,810 +10,990%
RRAM
18
River Road Asset Management
Kentucky
$31.2M +$37.6M +1,484,930 New
BFA
19
BlackRock Fund Advisors
California
$30.3M -$384K -15,171 -1%
GAM
20
Gotham Asset Management
New York
$27.6M +$8.86M +350,327 +36%
Tiger Global Management
21
Tiger Global Management
New York
$25.2M +$30.4M +1,202,100 New
PA
22
Pinnacle Associates
New York
$24.6M -$756K -29,900 -2%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$23.3M -$270K -10,672 -1%
NAP
24
New Amsterdam Partners
New York
$21.3M +$945K +37,346 +4%
LSV Asset Management
25
LSV Asset Management
Illinois
$20.1M +$24M +950,830 +16,394%
1
2 3 4 5

MYGN Hedge Fund Activity: Q4 2013 in Review

270 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2013, worth a combined $2.38B — down 9.4% from $2.62B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new MYGN positions and 48 closed out — a net gain of 3 holders — while 109 added to existing stakes and 90 trimmed.

The largest buyer was Luxor Capital Group, adding an estimated $73.2M. The largest seller was Manning & Napier Advisors, exiting entirely with an estimated $173M sold.

  • 270 institutional investors held Myriad Genetics (MYGN) as of Q4 2013, up from 267 in Q3 2013.
  • Funds reported $2.38B of Myriad Genetics stock for Q4 2013, down 9.4% quarter-over-quarter.
  • 51 funds opened new Myriad Genetics positions in Q4 2013 and 48 closed out, a net change of +3 holders.
  • The largest Myriad Genetics buyer in Q4 2013 was Luxor Capital Group, an estimated $73.2M added.
  • The largest Myriad Genetics seller in Q4 2013 was Manning & Napier Advisors, an estimated $173M sold.

Based on aggregated 13F filings for Q4 2013.